Sugioka Kyoko, Hayashi Akinobu, Ichishi Masako, Sugimoto Yasuko, Habe Koji, Yamanaka Keiichi
Department of Dermatology, Graduate School of Medicine, Mie University, Tsu, Mie 514-8507, Japan.
Department of Oncologic Pathology, Graduate School of Medicine, Mie University, Tsu, Mie 514-8507, Japan.
Dermatopathology (Basel). 2021 May 8;8(2):124-129. doi: 10.3390/dermatopathology8020018.
Lymphocytic infiltration of the skin (LIS), first reported by Jessner and Kanof in 1953, is a disease of unknown etiology characterized by erythematous papules and plaques on the head, neck, and upper back and histopathological findings of a normal epidermis with underlying lymphocytic infiltration of the reticular dermis without mucin deposition. A 69-year-old man and a 21-year-old woman presented with edematous indurative erythema of the left upper eyelid. Lymphocytic infiltration of the dermis with CD4+ T cell predominance was noted on biopsy. A 68-year-old man presented with a four-year history of recurrent edematous indurative erythema of the right upper eyelid that extended up to the right cheek. Predominantly dermal infiltration of CD8+ T lymphocytes was found on biopsy. We treated all three patients with 8-16 mg of methylprednisolone daily, and the erythema and induration improved. CD4+ T cells were predominant in the acute phase (patients 1 and 2), whereas CD8+ T cells were predominant in the chronic phase (patient 3). CD8+ T cells may be involved in LIS recurrence. Lymphocytic infiltration of the eyelid may be associated with isolated circumscribed, edematous, indurative, colorless lesions that are responsive to daily low-to-middle doses of oral methylprednisolone.
皮肤淋巴细胞浸润症(LIS)于1953年由杰斯纳(Jessner)和卡诺夫(Kanof)首次报道,是一种病因不明的疾病,其特征为头、颈和上背部出现红斑丘疹和斑块,组织病理学表现为表皮正常,网状真皮有淋巴细胞浸润但无黏蛋白沉积。一名69岁男性和一名21岁女性表现为左上眼睑水肿性硬结红斑。活检发现真皮淋巴细胞浸润,以CD4 + T细胞为主。一名68岁男性有右上眼睑反复出现水肿性硬结红斑4年的病史,该红斑向上延伸至右脸颊。活检发现主要为CD8 + T淋巴细胞的真皮浸润。我们对所有三名患者每日使用8 - 16毫克甲泼尼龙进行治疗,红斑和硬结均有改善。急性期(患者1和2)以CD4 + T细胞为主,而慢性期(患者3)以CD8 + T细胞为主。CD8 + T细胞可能与LIS复发有关。眼睑淋巴细胞浸润可能与孤立的、边界清晰的、水肿性的、硬结性的、无色病变有关,这些病变对每日低至中等剂量的口服甲泼尼龙有反应。